American Association for Cancer Research
Browse
15357163mct090499-sup-6_tablegs_2_figlegs.pdf (63.3 kB)

Legends for Supplementary Figures 1-2, Tables 1-6 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

Download (63.3 kB)
journal contribution
posted on 2023-03-31, 23:25 authored by Joan M. Carboni, Mark Wittman, Zheng Yang, Francis Lee, Ann Greer, Warren Hurlburt, Stephen Hillerman, Carolyn Cao, Glenn H. Cantor, Janet Dell-John, Cliff Chen, Lorell Discenza, Krista Menard, Aixin Li, George Trainor, Dolatrai Vyas, Robert Kramer, Ricardo M. Attar, Marco M. Gottardis
Legends for Supplementary Figures 1-2, Tables 1-6 from BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

History

ARTICLE ABSTRACT

BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, <2 nmol/L). It is currently in phase I development for the treatment of a variety of human cancers. BMS-754807 effectively inhibits the growth of a broad range of human tumor types in vitro, including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, gastric), and hematopoietic (multiple myeloma and leukemia) tumor cell lines (IC50, 5–365 nmol/L); the compound caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage. BMS-754807 is active in vivo in multiple (epithelial, mesenchymal, and hematopoietic) xenograft tumor models with tumor growth inhibition ranging from 53% to 115% and at a minimum effective dose of as low as 6.25 mg/kg dosed orally daily. Combination studies with BMS-754807 have been done on multiple human tumor cell types and showed in vitro synergies (combination index, <1.0) when combined with cytotoxic, hormonal, and targeted agents. The combination of cetuximab and BMS-754807 in vivo, at multiple dose levels, resulted in improved clinical outcome over single agent treatment. These data show that BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family–targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents. [Mol Cancer Ther 2009;8(12):3341–9]

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC